Company Overview and News

 
New Ecuadorian Government policy announced that could pave way for drilling to begin earlier at Bramaderos project in Ecuador

2018-07-16 globenewswire
OTTAWA, July 16, 2018 (GLOBE NEWSWIRE) -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP) (F:GWN) (B:GWN) (OTC:CTNXF) is pleased to announce an initiative by the Ecuadorian government to allow for “scout (reconnaissance) drilling” within exploration concessions. The initiative was announced by a representative of the Ecuadorian Ministry of Energy and Non-Renewable Natural Resources (MERNNR) during a presentation on July 10th at the “Investing in LATAM Mining Summit” in Santiago, Chile.
CTNXF STTMF AVI

 
Cornerstone announces 36m at 0.9g/t gold and 0.4% copper from initial trenching at Limon Prospect, Bramaderos Gold-Copper Project in Ecuador

2018-04-30 globenewswire
OTTAWA, April 30, 2018 (GLOBE NEWSWIRE) -- Cornerstone Capital Resources Inc. (“Cornerstone” or “the Company”) (TSXV:CGP) (Frankfurt:GWN) (Berlin:GWN) (OTC:CTNXF) announces the following initial trenching results from the Limon target at its Bramaderos Gold-Copper Project in southern Ecuador.
CTNXF STTMF AVI

4
Kin Mining appoints experienced Andrew Munckton as chief executive officer

2018-04-27 proactiveinvestors.com.au
As a geologist and holder of numerous executive roles with a wide range of mining companies, Munckton will be valuable in shaping the group’s strategy.
GDBGF SMD GBG NST NHRNY KIN NESRF AVI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AVI / AVALON MINERALS LIMITED on message board site Silicon Investor.

Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Avid Traders Chat ( Revisited ) Avid Traders Chat ( Revisited ) Avid Traders Chat ( Revisited )
Harley Davidson (HDI) Harley Davidson (HDI) Harley Davidson (HDI) Trimble Navigation Trimble Navigation Trimble Navigation
Cavium Cavium Cavium Aviat Networks Aviat Networks Aviat Networks
Avid Technology, Inc. Avid Technology, Inc. Avid Technology, Inc. Whou0027s Having an 80+ Birthday? Whou0027s Having an 80+ Birthday? Whou0027s Having an 80+ Birthday?
Auto Rental Companies - AVI, BD, HRZ, DTG, AN Auto Rental Companies - AVI, BD, HRZ, DTG, AN Auto Rental Companies - AVI, BD, HRZ, DTG, AN Psychology and Investment Behavior Psychology and Investment Behavior Psychology and Investment Behavior